Business · Companies · 3 hrs ago

Isomorphic Labs raises $5 billion to advance AI-designed drugs

Isomorphic Labs raises $5 billion to advance AI-designed drugs

London-based Isomorphic Labs raised $5 billion in a new funding round led by Greenoaks and Sequoia Capital.

The company is a spinout from Alphabet’s DeepMind and uses artificial intelligence to help design drugs.

The funding follows a $2.1 billion round in May, giving the company two of the biotech sector’s largest funding rounds this year.

Isomorphic says its work has produced positive early test results in cancer and immune-system research.

It plans to develop its technology and move drug candidates toward clinical trials, while also exploring more areas of biology.

No AI-designed medicine has been approved, and drug development remains uncertain, so the funding does not mean a treatment is ready for patients.

4 sources

Related

What people are saying

Isomorphic LabsCompany
expand deeper into new biology
via BioPharma Dive
setting the stage for clinical entry
via BioPharma Dive